ProKidney Corp. (NASDAQ:PROK) Given Average Recommendation of “Hold” by Brokerages

Shares of ProKidney Corp. (NASDAQ:PROK) have earned a consensus rating of “Hold” from the seven research firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $7.40.

A number of research analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of ProKidney in a research note on Wednesday, October 8th. HC Wainwright initiated coverage on ProKidney in a research report on Tuesday. They issued a “buy” rating and a $12.00 price target on the stock.

Insider Transactions at ProKidney

In other ProKidney news, Director Brian Jg Pereira sold 502,136 shares of the firm’s stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $2.37, for a total value of $1,190,062.32. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 41.49% of the stock is owned by company insiders.

Hedge Funds Weigh In On ProKidney

Institutional investors and hedge funds have recently bought and sold shares of the stock. Zullo Investment Group Inc. acquired a new position in ProKidney in the 3rd quarter valued at approximately $28,000. AQR Capital Management LLC grew its holdings in shares of ProKidney by 106.4% during the 1st quarter. AQR Capital Management LLC now owns 52,570 shares of the company’s stock worth $46,000 after purchasing an additional 27,098 shares in the last quarter. Deutsche Bank AG increased its position in shares of ProKidney by 49.4% during the first quarter. Deutsche Bank AG now owns 86,337 shares of the company’s stock valued at $76,000 after purchasing an additional 28,546 shares during the period. Two Sigma Investments LP raised its stake in shares of ProKidney by 40.4% in the third quarter. Two Sigma Investments LP now owns 99,282 shares of the company’s stock valued at $240,000 after purchasing an additional 28,583 shares in the last quarter. Finally, UBS Group AG lifted its position in ProKidney by 7.0% in the third quarter. UBS Group AG now owns 508,353 shares of the company’s stock worth $1,230,000 after purchasing an additional 33,306 shares during the period. Institutional investors own 51.59% of the company’s stock.

ProKidney Stock Performance

Shares of PROK stock opened at $2.47 on Friday. The stock’s 50 day simple moving average is $2.62 and its 200 day simple moving average is $2.37. ProKidney has a twelve month low of $0.46 and a twelve month high of $7.13. The company has a market capitalization of $743.05 million, a price-to-earnings ratio of -4.49 and a beta of 1.79.

ProKidney (NASDAQ:PROK) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12). The company had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.04 million. On average, analysts forecast that ProKidney will post -0.57 EPS for the current fiscal year.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.